Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05130255 · ClinicalTrials.gov registry record · Phase 1

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

A Phase 1 study of Sarcoma and Malignant Melanoma, sponsored by Y-mAbs Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
8
Study locations

NCT05130255 is a Phase 1 study of Sarcoma and Malignant Melanoma that is actively recruiting participants, run by Y-mAbs Therapeutics. The registered enrollment target is 60 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05130255, a Phase 1 study of Sarcoma and Malignant Melanoma, is actively recruiting participants, sponsored by Y-mAbs Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
8
Study locations

Study Summary

Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability

Conditions Studied

Sarcoma Malignant Melanoma SCLC High-risk Neuroblastoma

Interventions

  • DRUG GD2-SADA:177Lu-DOTA Complex

Study Locations (8)

Arizona

  • HonorHealth - Scottsdale

California

  • City of Hope National Medical Center - Duarte

Illinois

  • University of Chicago - Chicago

Michigan

  • Corewell Health-BAMF Health - Grand Rapids

New York

  • Memorial Sloan- Kettering Cancer Center - New York

Ohio

  • Case Western Reserve University, Cleveland - Cleveland

Pennsylvania

  • UPMC Hillman Cancer Center - Pittsburgh

Wisconsin

  • University of Wisconsin-Madison - Madison

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2022-11-17
Est. Completion 2027-04
Phase Phase 1

Sponsor

Y-mAbs Therapeutics

11 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05130255

The ClinicalTrials.gov registry entry for NCT05130255 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (93% lower). The listed sponsor is Y-mAbs Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which GD2-SADA:177Lu-DOTA Complex is the first listed.

NCT05130255 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Arizona, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT05130255 about?

NCT05130255 is a clinical study titled "GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2". Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability

What is the current status of trial NCT05130255?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2022-11-17. Estimated completion is 2027-04.

What conditions does trial NCT05130255 study?

This clinical trial studies the following conditions: Sarcoma, Malignant Melanoma, SCLC, High-risk Neuroblastoma.

What interventions are being tested in trial NCT05130255?

The interventions under investigation include: GD2-SADA:177Lu-DOTA Complex (DRUG).

Who is sponsoring clinical trial NCT05130255?

This trial is sponsored by Y-mAbs Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05130255 being conducted?

This trial has 8 study locations across Arizona, California, Illinois, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sarcoma

All registered trials for this condition

Malignant Melanoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.